segluromet
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
steglujan
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic skābes, sitagliptin fosfāts monohidrāts - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan ir norādīts pieaugušajiem vecumā no 18 gadiem un vecāki ar 2. tipa cukura diabētu, kā palīglīdzekli, lai diētu un vingrinājumiem, lai uzlabotu glycaemic kontrole:ja metformīns un/vai sulfonilurīnvielas pamata, (su), un viens no monocomponents no steglujan nenodrošina pietiekamu kontroles glycaemic. pacientiem, kas jau tiek ārstēti ar kombināciju ertugliflozin un sitagliptin kā atsevišķas tabletes.
l-thyroxin berlin-chemie 150 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 150 μg
l-thyroxin berlin-chemie 100 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 100 μg
l-thyroxin berlin-chemie 50 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 50 μg
l-thyroxin berlin-chemie 125 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 125 μg
l-thyroxin berlin-chemie 75 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 75 μg
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
sitagliptin/metformin hydrochloride teva 50 mg/850 mg apvalkotās tabletes
teva gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg